Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis
Donna H. Ryan, Angela Fitch, Robert F. Kushner, Jena S. Tronieri, Christopher D. Still, Caroline M. Apovian · 2026
Read Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis by Donna H. Ryan, Angela Fitch, Robert F. Kushner, Jena S. Tronieri, Christopher D. Still, Caroline M. Apovian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13270069.txt.
Description
Donna H Ryan and co-authors published a journal article in 2026 re-analyzing three phase 3 trials of a two-drug obesity treatment, naltrexone plus bupropion in extended-release form. The analysis covered 1,692 patients and focused on those who finished treatment and took at least 90 percent of doses. It asked which starting traits predict hitting weight targets at 56 weeks.
Among the highly adherent treated patients, seventy-three point two percent lost at least 5 percent of body weight. Losses of 10 percent and 15 percent were reached by forty-seven point six and twenty-seven point eight percent. Target body mass index was hit by thirty-three point seven percent and target waist size by twenty-three point seven percent. Female sex and White race most consistently predicted success. Advance prediction stayed limited, the authors conclude.
Catalog record
| CREATOR | Donna H. Ryan, Angela Fitch, Robert F. Kushner, Jena S. Tronieri, Christopher D. Still, Caroline M. Apovian |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44130 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |